Free  Paradigm(s)

Marketing Authorisations

Ivosidenib (Tibsovo°) in the first-line treatment of acute myeloid leukaemia with an IDH1 mutation

Editors' opinion. Informed choices

Ivosidenib (Tibsovo°) as second- or subsequent-line therapy in certain cholangio­carcinomas

Niraparib + abiraterone (Akeega°) in BRCA-mutated metastatic prostate cancer that is resistant to androgen deprivation therapy

Tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat (Genvoya°) in HIV infection from 2 years of age

Sutimlimab (Enjaymo°) in cold agglutinin disease

Mirikizumab (Omvoh°) in ulcerative colitis

Futibatinib (Lytgobi°) as second-line treatment for inoperable or metastatic cholangio­carcinoma with an FGFR2 mutation

Raloxifene and teriparatide in the prevention of osteoporotic fractures in postmenopausal women

Adverse Effects

Levetiracetam in utero: long-term effects more clearly defined

Cholinesterase inhibitors: depression, insomnia, anorexia

Domperidone, metoclopramide and other neuroleptics used as antiemetics: parkinsonism

SSRI anti­depressants and oral anti­coagulants: bleeding

Long-term methylphenidate use: cardio­vascular disorders

Ciclosporin: fibroadenomas of the breast

Common stem: -salazine

Outlook

Free  Mediator° disaster: the damning appeal judgement

An obvious chemical relationship

Free  New data after marketing authorisation: European Commission consultation (continued)

Free  EMA: two surveys about the patient leaflet

Masthead

Free  Masthead